ACOR: Summary for Acorda Therapeutics, Inc. - Yahoo! Canada Finance

	Sign In [New User? Sign Up]	Finance Home \|Help

Wednesday, February 10, 2010, 8:19am EST - Canadian Markets open in 1 hour and 11 minutes.

To create a watchlist or portfolio of shares, Sign-in or Register

Acorda Therapeutics, Inc. (ACOR)

On Feb 9: 29.99 USD 0.00 (0.00%)

MORE ON ACOR

Quotes

Summary

Charts

News & Info

Company

Analyst Coverage

Ownership

Financials

Acorda Therapeutics, Inc. (NGM:ACOR) Delayed quote data

Last Trade:	29.99 USD
Trade Time:	Feb 9
Change:	0.00 (0.00%)
Prev Close:	29.99
Open:	N/A
Bid:	27.52 x 400
Ask:	30.59 x 200
1y Target Est:	33.63

Day's Range:	N/A - N/A
52wk Range:	15.52 - 31.78
Volume:	0
Avg Vol (3m):	785,676
Market Cap:	1.14B
P/E (ttm):	N/A
EPS (ttm):	-2.17
Div & Yield:	N/A (N/A%)

1d 5d 3m 6m 1y 2y 5y

Add ACOR to Portfolio

Download Data

HEADLINES

•	Cramer's Lighting Round - Dole Is in the Hole (2/9/10)
	at Seeking Alpha (Wed 6:29am)

•	Lightning Round: Acodra Therapeutics, Dole Food, Valmont Industries and More
	at CNBC (Tue 9:24pm)

•	'Mad Money Lightning Round': Rambus Heading Higher
	at TheStreet.com (Tue 7:35pm)

•	Cramer's 'Mad Money' Recap: The Catalysts Behind the Rally (Final)
	at TheStreet.com (Tue 7:26pm)

•	[video] Acorda Therapeutics CEO on Drug Pricing
	at CNBC (Mon, Feb 8)

•	4 Winning Biotechs For Your Portfolio: Senior Analyst
	at CNBC (Mon, Feb 8)

•	Is Biotech Back?
	CNBC (Mon, Feb 8)

•	[video] Is Biotech Back?
	at CNBC (Mon, Feb 8)

•	Wild Weekly Wrap-Up: Everyone Just Relax
	at Seeking Alpha (Mon, Feb 8)

•	Acorda Therapeutics downgraded by Robert W. Baird
	Briefing.com (Thu, Feb 4)

•	Acorda's Lucky Number 13
	at CNBC (Wed, Feb 3)

•	Acorda Therapeutics to Present at the 12th Annual BIO CEO & Investor Conference
	Business Wire (Wed, Feb 3)

•	ACORDA THERAPEUTICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
	EDGAR Online (Wed, Feb 3)

•	Acorda Therapeutics Announces Pricing and Patient Assistance Programs for AMPYRA (dalfampridine)
	Business Wire (Wed, Feb 3)

More Headlines for ACOR...

ANALYST

EPS Est (next year) (Dec-09) :	-2.22
EPS Est (in 2 years) (Dec-10) :	-1.75
Avg Rec (current)*:	2.2
PEG Ratio:	N/A

* (Strong Buy) 1.0 - 5.0 (Strong Sell)

Analyst Opinion - Estimates

BUSINESS SUMMARY

Acorda Therapeutics, Inc., a biopharmaceutical company, engages in the identification, development, and commercialization of various therapies for the improvement of neurological functions in people with multiple sclerosis (MS), spinal cord injury...

Full Company Profile

Add to Portfolio

Email to a Friend

•